Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis ; volume:23 ; number:1 ; day:23 ; month:7 ; year:2021 ; pages:1-10 ; date:12.2021
Arthritis Research & Therapy ; 23, Heft 1 (23.7.2021), 1-10, 12.2021
- Urheber
-
Iwamoto, Naoki
Sato, Shuntaro
Kurushima, Shota
Michitsuji, Toru
Nishihata, Shinya
Okamoto, Momoko
Tsuji, Yoshika
Endo, Yushiro
Shimizu, Toshimasa
Sumiyoshi, Remi
Suzuki, Takahisa
Okada, Akitomo
Koga, Tomohiro
Kawashiri, Shin-ya
Fujikawa, Keita
Igawa, Takashi
Aramaki, Toshiyuki
Ichinose, Kunihiro
Tamai, Mami
Nakamura, Hideki
Mizokami, Akinari
Origuchi, Tomoki
Ueki, Yukitaka
Eguchi, Katsumi
Kawakami, Atsushi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-021-02582-z
- URN
-
urn:nbn:de:101:1-2021102319193893137596
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Iwamoto, Naoki
- Sato, Shuntaro
- Kurushima, Shota
- Michitsuji, Toru
- Nishihata, Shinya
- Okamoto, Momoko
- Tsuji, Yoshika
- Endo, Yushiro
- Shimizu, Toshimasa
- Sumiyoshi, Remi
- Suzuki, Takahisa
- Okada, Akitomo
- Koga, Tomohiro
- Kawashiri, Shin-ya
- Fujikawa, Keita
- Igawa, Takashi
- Aramaki, Toshiyuki
- Ichinose, Kunihiro
- Tamai, Mami
- Nakamura, Hideki
- Mizokami, Akinari
- Origuchi, Tomoki
- Ueki, Yukitaka
- Eguchi, Katsumi
- Kawakami, Atsushi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib
Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on Baricitinib
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
The effect of JAK inhibitors baricitinib and tofacitinib on Th17 cells, regulatory T cells and the Th17/Treg balance in patients with rheumatoid arthritis
Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis
Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review
Interaktion der Tyrosinkinase-Inhibitoren Baricitinib und Tofacitinib mit Transportern für organische Kationen
Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib
Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on Baricitinib
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
The effect of JAK inhibitors baricitinib and tofacitinib on Th17 cells, regulatory T cells and the Th17/Treg balance in patients with rheumatoid arthritis
Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis
Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review
Interaktion der Tyrosinkinase-Inhibitoren Baricitinib und Tofacitinib mit Transportern für organische Kationen
Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib
Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on Baricitinib
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
The effect of JAK inhibitors baricitinib and tofacitinib on Th17 cells, regulatory T cells and the Th17/Treg balance in patients with rheumatoid arthritis
Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis
Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review